Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Roginolisib, Venetoclax, and Rituximab in Relapsed/Refractory CLL
NCT06644183Phase 2Recruiting
- Start
- Mar 2025
- Primary completion
- Oct 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of roginolisib in chronic lymphocytic leukemia (CLL). Started Mar 2025; status: recruiting.
02
Drugs
roginolisib
03
Conditions
chronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT06644183.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06644183.